Olorinab (APD371), a peripherally acting, highly selective, full agonist of the cannabinoid receptor 2, reduces colitis-induced acute and chronic visceral hypersensitivity in rodents-Reference-Cited by-同舟云学术

Olorinab (APD371), a peripherally acting, highly selective, full agonist of the cannabinoid receptor 2, reduces colitis-induced acute and chronic visceral hypersensitivity in rodents

Published:2021-04-13 Issue:1 Volume:163 Page:e72-e86
ISSN:0304-3959
Container-title:Pain
language:en
Short-container-title:PAIN

Author:

Castro Joel,Garcia-Caraballo Sonia,Maddern Jessica,Schober Gudrun,Lumsden Amanda,Harrington Andrea,Schmiel Shirdi,Lindstrom Beatriz,Adams John,Brierley Stuart M.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Anesthesiology and Pain Medicine,Neurology (clinical),Neurology

Reference63 articles.

1. Severity of mucosal inflammation as a predictor for alterations of visceral sensory function in a rat model;Adam;PAIN,2006

2. APD371: a Potent, highly selective, full agonist of the human CB2 receptor with sustained analgesic effects in rodents;Adams;J Pain,2018

3. Enterochromaffin cells are gut chemosensors that couple to sensory neural pathways;Bellono;Cell,2017

4. Palmitoylethanolamide, a naturally occurring lipid, is an orally effective intestinal anti-inflammatory agent;Borrelli;Br J Pharmacol,2015

5. Splanchnic and pelvic mechanosensory afferents signal different qualities of colonic stimuli in mice;Brierley;Gastroenterology,2004

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Impact of the CB2 Cannabinoid Receptor in Inflammatory Diseases: An Update;Molecules;2024-07-18

2. Chronic Visceral Pain: New Peripheral Mechanistic Insights and Resulting Treatments;Gastroenterology;2024-06

3. Emerging potential therapies for chronic abdominal visceral pain: an overview;Advancements in Health Research;2024-03-18

4. Drugs of the future for diarrhea-predominant irritable bowel syndrome: an overview of current investigational drugs;Expert Opinion on Investigational Drugs;2024-02-23

5. Cannabinoids and the Gastrointestinal Tract;Clinical Gastroenterology and Hepatology;2023-12